Your browser does not support JavaScript!
COVID-19 : Découvrez les Plans de Continuité d’Activité des entreprises de la biotechnologies
Logo de Labiotech.eu

Labiotech.eu Source d'actualité

Une actualité de Labiotech.eu a été ajouté(e)
Il y a 3 jours
Winning at Your Drug Development Strategy: A Playbook for Emerging Biotechs
The global biotech industry is driven by innovation, and emerging biotechs are at the wheel. Emerging biotechs are taking control of drug development pipelines. In 2018, 74% of new drugs launched were...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 3 jours
Guidelines for Biotechs: Managing Risks in Biological Drug Development
Navigating the complexity of the industry can be highly challenging for early-stage biotechs focusing on biological drug development. Once they have a robust strategy in place and have chosen a...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 3 jours
Freeline Closes €106M Series C to Progress Hemophilia Gene Therapy
UK biotech Freeline Therapeutics has extended its Series C round to take its gene therapy for hemophilia B to a pivotal trial, while hinting at the possibility of an IPO in the US later this...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 4 jours
Why Biotech Must Change its Cleaning and Disinfection Strategy
Many biotech companies deploy strong chemicals to clean and disinfect their equipment. However, if handled in the wrong way, this can lead to dangerous problems such as antibiotic resistance. As the...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 4 jours
Swiss Regenerative Medicine Biotech Closes €19M Series B
The regenerative medicine startup Cutiss has raised €18.8M (CHF 20M) to commercialize its personalized skin graft treatment for burn patients in Switzerland and the European Union around 2022. This is...
www.labiotech.eu
Charger plus d'actualités

Informations juridiques
SIREN / SIRET - DE Labiotech

Adresse
Berlin Berlin DE Allemagne